Cancer Vaccines as Immunotherapy of Cancer
Editat de Luigi Buonaguro, Sjoerd Van Der Burgen Limba Engleză Paperback – 23 mar 2022
The book discusses topics such as identification of tumor associated and specific antigens, proteogenomic for identification of novel target tumor antigens, antigen-specific T cells, and Peptide and RNA based vaccines. Additionally, it covers oncolytic viruses for antigen delivery, cancer vaccine targeting viral antigens and combinatorial immunotherapy strategies.
Written by leading experts worldwide, this is a valuable resource for cancer researchers, oncologists and members of biomedical field who wants to understand in depth the recent findings in the field of cancer vaccines.
- Describes the state-of-the-art of the research and development of therapeutic cancer vaccines
- Presents detailed diagrams to help the reader understand the functionality of each type of vaccine discussed
- Encompasses recent findings in the field through chapters written by leading experts worldwide
Preț: 684.40 lei
Preț vechi: 898.94 lei
-24% Nou
Puncte Express: 1027
Preț estimativ în valută:
131.02€ • 136.19$ • 108.63£
131.02€ • 136.19$ • 108.63£
Carte tipărită la comandă
Livrare economică 30 ianuarie-13 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128239018
ISBN-10: 0128239018
Pagini: 272
Ilustrații: 30 illustrations (15 in full color)
Dimensiuni: 152 x 229 x 19 mm
Greutate: 0.37 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0128239018
Pagini: 272
Ilustrații: 30 illustrations (15 in full color)
Dimensiuni: 152 x 229 x 19 mm
Greutate: 0.37 kg
Editura: ELSEVIER SCIENCE
Cuprins
1. Introduction2. Identification of Tumor Associated Antigens3. Identification of Tumor Specific Antigens4. Proteogenomics for identification of novel target tumor antigens5. Antigen-specific T cells6. Tumor antigens for preventive strategies7. Peptide based vaccines8. RNA based vaccines9. Novel dendritic cells strategies10. Oncolytic viruses for antigen delivery11. Cancer vaccine targeting viral antigens12. Combinatorial immunotherapy strategies13. Conclusions